 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Æterna Zentaris Inc.
|
-
AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
(05/16/2008)
AEterna Zentaris Inc. reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH).Cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) ...
-
AEterna Zentaris Announces Changes to its Management Team
(04/15/2008)
AEterna Zentaris Inc. announced that David J. Mazzo, Ph.D., has resigned as President and Chief Executive Officer and as member of the Board of Directors of AEterna Zentaris, effective immediately. Mr. Juergen Ernst, the current Chairman of the ...
-
Jado Technologies licences clinical data from Æterna Zentaris for use of Miltefosine in allergy indications
(11/01/2007)
Dresden based biotech JADO Technologies today signed an agreement with Aeterna Zentaris for access to clinical data for the marketed drug miltefosine. JADO believes its proprietary technology is able to identify additional indications for the drug, ...
-
AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112
(10/29/2007)
AEterna Zentaris Inc. presented an abstract outlining novel data generated from three AEZS-112 (formerly ZEN-012) follow-up multi-targeted cytotoxic candidates at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...
-
Æterna Zentaris Completes Management Team with the Appointment of Chief Medical Officer
(08/21/2007)
Æterna Zentaris Inc. announced the filling of a key position completing the management team with the appointment of Paul Blake, M.D., as Senior Vice President and Chief Medical Officer.Prior to joining Æterna Zentaris, Dr. Blake was Chief Medical ...
-
Æterna Zentaris Announces Appointment of New President and CEO
(03/29/2007)
Æterna Zentaris Inc. announced the appointment of David J. Mazzo, Ph.D. as President and Chief Executive Officer (CEO), effective on April 9, 2007. Dr. Mazzo succeeds Gilles Gagnon who is leaving his position as President and CEO and as a member of ...
-
AEterna Zentaris Completes Distribution of Remaining Shares of Atrium Biotechnologies
(01/05/2007)
AEterna Zentaris Inc. announced that it has completed the special distribution in kind of all of the 11,052,996 subordinate voting shares of the capital of Atrium Biotechnologies Inc. previously held by AEterna Zentaris by way of return of capital ...
-
Æterna Zentaris appoints former Abbott Vice President to its Board of Directors
(01/27/2006)
Æterna Zentaris Inc. announced the appointment to its Board of Directors of Gerald J. Martin, former Vice President, Corporate Licensing and Technology Alliances at Abbott Laboratories. Mr. Martin, former Vice President, Corporate Licensing and ...
-
AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix Phase II Trial in Benign Prostatic Hyperplasia
(11/23/2005)
AEterna Zentaris Inc. announced it has completed enrollment of 144 patients for a Phase II trial with ozarelix (D-63153) in benign prostatic hyperplasia (BPH), more than four months ahead of schedule. The randomized, placebo-controlled multi-center ...
|
|
|
|
|
Top